Ritodrina [Inn-Spanish] en es it fr

Ritodrina [Inn-Spanish] Brand names, Ritodrina [Inn-Spanish] Analogs

Ritodrina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Ritodrina [Inn-Spanish] Chemical_Formula


Ritodrina [Inn-Spanish] RX_link

No information avaliable

Ritodrina [Inn-Spanish] fda sheet

Ritodrina [Inn-Spanish] msds (material safety sheet)

Ritodrina_[Inn-Spanish] MSDS

Ritodrina [Inn-Spanish] Synthesis Reference

Belg. pat. 660.244 (1965 to N.V. Philips), C.A. 63, 17965h (1965) corresp to Claassen et al., U.S. pat. 3,410,944 (1968 to No. Am. Philips)

Ritodrina [Inn-Spanish] Molecular Weight

287.354 g/mol

Ritodrina [Inn-Spanish] Melting Point

88-90 oC

Ritodrina [Inn-Spanish] H2O Solubility


Ritodrina [Inn-Spanish] State


Ritodrina [Inn-Spanish] LogP


Ritodrina [Inn-Spanish] Dosage Forms

Solution for IV; Capsule (extended-release); Tablet; Intramuscular injection

Ritodrina [Inn-Spanish] Indication

For the treatment and prophylaxis of premature labour

Ritodrina [Inn-Spanish] Pharmacology

Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle.

Ritodrina [Inn-Spanish] Absorption

No information avaliable

Ritodrina [Inn-Spanish] side effects and Toxicity

LD50=64mg/kg (mice, IV); LD50=540 mg/kg (mice, oral); LD50=85 mg/kg (rat, IV)

Ritodrina [Inn-Spanish] Patient Information

Ritodrina [Inn-Spanish] Organisms Affected

Humans and other mammals